TW200716084A - Methods for treating sleep-wake disorders - Google Patents

Methods for treating sleep-wake disorders

Info

Publication number
TW200716084A
TW200716084A TW095120134A TW95120134A TW200716084A TW 200716084 A TW200716084 A TW 200716084A TW 095120134 A TW095120134 A TW 095120134A TW 95120134 A TW95120134 A TW 95120134A TW 200716084 A TW200716084 A TW 200716084A
Authority
TW
Taiwan
Prior art keywords
carbon atoms
hydrogen
group
oxygen atom
methods
Prior art date
Application number
TW095120134A
Other languages
English (en)
Other versions
TWI419681B (zh
Inventor
Abdallah Ahnaou
Wilhelmus H I M Drinkenburg
Joseph M Palumbo
Jonathan Sporn
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37085728&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200716084(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of TW200716084A publication Critical patent/TW200716084A/zh
Application granted granted Critical
Publication of TWI419681B publication Critical patent/TWI419681B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
TW095120134A 2005-06-08 2006-06-07 胺基甲酸酯用於製造供治療白天過度嗜睡（eds）的藥物之用途 TWI419681B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68863805P 2005-06-08 2005-06-08

Publications (2)

Publication Number Publication Date
TW200716084A true TW200716084A (en) 2007-05-01
TWI419681B TWI419681B (zh) 2013-12-21

Family

ID=37085728

Family Applications (2)

Application Number Title Priority Date Filing Date
TW095120134A TWI419681B (zh) 2005-06-08 2006-06-07 胺基甲酸酯用於製造供治療白天過度嗜睡（eds）的藥物之用途
TW101130937A TW201328689A (zh) 2005-06-08 2006-06-07 治療睡眠-覺醒病症之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW101130937A TW201328689A (zh) 2005-06-08 2006-06-07 治療睡眠-覺醒病症之方法

Country Status (16)

Country Link
US (6) US8440715B2 (zh)
EP (1) EP1890684B1 (zh)
JP (1) JP5024635B2 (zh)
KR (1) KR101335941B1 (zh)
CN (1) CN101217949B (zh)
AU (1) AU2006254899B2 (zh)
BR (1) BRPI0613697A2 (zh)
CA (1) CA2611713C (zh)
DK (1) DK1890684T3 (zh)
ES (1) ES2435403T3 (zh)
FR (1) FR20C1014I2 (zh)
NL (1) NL301037I2 (zh)
PL (1) PL1890684T3 (zh)
RU (1) RU2417077C2 (zh)
TW (2) TWI419681B (zh)
WO (1) WO2006133393A1 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1890684T3 (pl) 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
KR101335942B1 (ko) * 2005-06-22 2013-12-04 에스케이바이오팜 주식회사 성기능 장애의 치료
IN2012DN00624A (zh) * 2009-06-22 2015-06-12 Sk Biopharmaceuticals Co Ltd
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
JP5836280B2 (ja) * 2009-11-06 2015-12-24 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
JP5901528B2 (ja) * 2009-11-06 2016-04-13 エスケー バイオファーマスティカルズ カンパニー リミテッド 線維筋痛症候群の治療方法
US9610274B2 (en) * 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
KR102192554B1 (ko) 2013-03-13 2020-12-18 에스케이바이오팜 주식회사 탈력발작의 치료
KR102309836B1 (ko) * 2013-07-18 2021-10-12 에스케이바이오팜 주식회사 비만의 치료
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI655179B (zh) 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
JP6466792B2 (ja) * 2015-07-03 2019-02-06 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
TWI637765B (zh) * 2016-05-10 2018-10-11 台灣共振波研發股份有限公司 Soothing device for attention deficit hyperactivity disorder
US10829443B2 (en) 2016-09-06 2020-11-10 Jazz Pharmaceuticals Ireland Limited Solvate form of (R)-2-amino-3-phenylpropyl carbamate
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
ES2964943T3 (es) 2016-10-06 2024-04-10 Axsome Malta Ltd Compuestos de carbamoilfenilalaninol para uso médico
KR20200016889A (ko) 2017-06-02 2020-02-17 재즈 파마슈티칼즈 아일랜드 리미티드 과다 졸림증을 치료하기 위한 방법 및 조성물
CN111094238B (zh) * 2017-07-31 2023-06-09 杰资制药爱尔兰有限公司 氨基甲酰基苯丙氨醇类似物及其用途
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
US11033214B1 (en) * 2020-05-19 2021-06-15 United Arab Emirates University Wearable eye tracking system
KR102390194B1 (ko) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939660A1 (de) * 1979-09-29 1981-04-16 Basf Ag, 6700 Ludwigshafen Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
IL109872A (en) 1993-06-10 2000-12-06 Lilly Co Eli Tetrahydrobenz ¬CD¾ indole-6-carboxamides for use in preventing emesis and pharmaceutical compositions comprising same
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) * 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) * 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
PT873308E (pt) 1996-10-10 2002-06-28 Sk Corp Compostos de o-carbamoil-fenilalaninol seus sais farmaceuticamente uteis e processo para a preparacao dos mesmos
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
PL364679A1 (en) * 2001-02-27 2004-12-13 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating movement disorders
CZ20032300A3 (cs) * 2001-02-27 2005-01-12 Ortho-Mcneil Pharmaceutical, Inc. Léčivo pro prevenci nebo léčbu bipolárních chorob
JP2004523554A (ja) * 2001-02-27 2004-08-05 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 不安障害の予防もしくは治療における使用のためのカルバメート化合物
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
BRPI0518233A2 (pt) 2004-10-28 2008-11-11 Sk Corp terapia adjunta para depressço
PL1890684T3 (pl) 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
KR101335942B1 (ko) 2005-06-22 2013-12-04 에스케이바이오팜 주식회사 성기능 장애의 치료
WO2007018496A1 (en) 2005-07-26 2007-02-15 Janssen Pharmaceutica, N.V. Methods for treating substance-related disorders
CN101557804A (zh) 2006-10-13 2009-10-14 詹森药业有限公司 氨基甲酸苯基烷基氨基酯组合物
IN2012DN00624A (zh) 2009-06-22 2015-06-12 Sk Biopharmaceuticals Co Ltd
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
JP5836280B2 (ja) 2009-11-06 2015-12-24 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
JP5901528B2 (ja) 2009-11-06 2016-04-13 エスケー バイオファーマスティカルズ カンパニー リミテッド 線維筋痛症候群の治療方法
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
KR102005483B1 (ko) 2012-10-19 2019-07-31 삼성디스플레이 주식회사 박막 트랜지스터 기판 및 그의 수리 방법
KR102192554B1 (ko) * 2013-03-13 2020-12-18 에스케이바이오팜 주식회사 탈력발작의 치료

Also Published As

Publication number Publication date
EP1890684A1 (en) 2008-02-27
CN101217949A (zh) 2008-07-09
US10351517B2 (en) 2019-07-16
AU2006254899B2 (en) 2011-11-24
US20190367448A1 (en) 2019-12-05
DK1890684T3 (da) 2013-10-14
JP2008545795A (ja) 2008-12-18
US9604917B2 (en) 2017-03-28
RU2008100019A (ru) 2009-07-20
EP1890684B1 (en) 2013-08-14
FR20C1014I1 (zh) 2020-06-12
WO2006133393A1 (en) 2006-12-14
CA2611713C (en) 2013-10-01
US8877806B2 (en) 2014-11-04
NL301037I2 (nl) 2020-05-12
KR20080035565A (ko) 2008-04-23
BRPI0613697A2 (pt) 2011-01-25
TWI419681B (zh) 2013-12-21
US20210078943A1 (en) 2021-03-18
TW201328689A (zh) 2013-07-16
PL1890684T3 (pl) 2014-05-30
NL301037I1 (zh) 2020-04-01
US8440715B2 (en) 2013-05-14
CN101217949B (zh) 2012-10-17
US20170158622A1 (en) 2017-06-08
US11753368B2 (en) 2023-09-12
AU2006254899A1 (en) 2006-12-14
KR101335941B1 (ko) 2013-12-04
US20090312416A1 (en) 2009-12-17
ES2435403T3 (es) 2013-12-19
RU2417077C2 (ru) 2011-04-27
FR20C1014I2 (fr) 2021-04-23
US20140350098A1 (en) 2014-11-27
CA2611713A1 (en) 2006-12-14
US20130137764A1 (en) 2013-05-30
JP5024635B2 (ja) 2012-09-12

Similar Documents

Publication Publication Date Title
TW200716084A (en) Methods for treating sleep-wake disorders
TW200727893A (en) Methods for treating sexual dysfunction
BRPI0518233A2 (pt) terapia adjunta para depressço
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
WO2007095174A3 (en) Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
TW200745034A (en) New compounds
TW200612958A (en) Substituted imidazole derivatives
CA2617817A1 (en) Thiazole derivatives for treating or preventing sleep disorders
PL1753723T3 (pl) Podstawione pochodne chinoliny jako inhibitory kinezyn mitotycznych
MX2009002802A (es) Derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas, su preparacion y su aplicacion en terapeutica.
RU2007143505A (ru) Производные ацетилена
WO2006136837A3 (en) Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
AU2006325931A8 (en) Amine compound and use thereof for medical purposes
GB0100623D0 (en) Chemical compounds IV
MY143605A (en) Tri-, tetra-substituted-3-aminopyrrolidine derivative
RU2012155118A (ru) Способы лечения биполярного расстройства
WO2006040569A8 (en) Thiophene amide compounds for use in the treatment or prophylaxis of cancers
NO20024906D0 (no) Antitumorale ekteinascidinderivater
CA2240060A1 (en) O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
WO2005046672A3 (fr) Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose
PT1202959E (pt) Aminobenzofenonas como inibidores de il-1-beta e tnf-alfa
MXPA05008706A (es) 4-[(2, 4- dicloro-5 -metoxifenil) amino]-6 -alcoxi -3- quinolincarbonitrilos para tratamiento de lesiones isquemicas.
WO2009008345A1 (ja) 金属錯体化合物、これを有効成分とする癌治療剤組成物および該金属錯体化合物用の中間体
ZA200703275B (en) 4 [(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinollnecarbonitriles for the treatment of ischemic Injury
ATE229538T1 (de) 22r-hydroxycholesta-8,14-diene derivate zur hemmung der meiose